Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

How should you guide patients on GLP-1 therapy who are planning pregnancy? Dr Almandoz breaks down when to stop treatment, ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

South Africa's Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

A boost for the category, and perhaps even a change in the way products are marketed, is anticipated based on research ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within 1 year.

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...